NasdaqGS:TLRY

Stock Analysis Report

Executive Summary

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis.

Snowflake

Fundamentals

High growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has Tilray's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.4%

TLRY

0.06%

US Pharmaceuticals

0.5%

US Market


1 Year Return

-82.6%

TLRY

-7.8%

US Pharmaceuticals

6.8%

US Market

Return vs Industry: TLRY underperformed the US Pharmaceuticals industry which returned -7.8% over the past year.

Return vs Market: TLRY underperformed the US Market which returned 6.8% over the past year.


Shareholder returns

TLRYIndustryMarket
7 Day3.4%0.06%0.5%
30 Day-26.3%-1.7%-0.8%
90 Day-50.3%-1.3%-0.9%
1 Year-82.6%-82.6%-5.5%-7.8%9.2%6.8%
3 Yearn/a18.4%10.1%45.6%36.2%
5 Yearn/a22.2%9.3%63.2%45.4%

Price Volatility Vs. Market

How volatile is Tilray's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Tilray undervalued compared to its fair value and its price relative to the market?

5.78x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TLRY's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate TLRY's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: TLRY is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: TLRY is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TLRY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TLRY is overvalued based on its PB Ratio (5.8x) compared to the US Pharmaceuticals industry average (2.9x).


Next Steps

Future Growth

How is Tilray forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?

64.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TLRY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).

Earnings vs Market: TLRY is forecast to become profitable over the next 3 year, which is considered above average market growth.

High Growth Earnings: TLRY's loss is forecast to worsen by 0% next year.

Revenue vs Market: TLRY's revenue (40.7% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: TLRY's revenue (40.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if TLRY's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Tilray performed over the past 5 years?

-407.1%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: TLRY is unprofitable, and there is insufficient past data to establish if their past 5-year earnings growth rate was positive.

Accelerating Growth: Unable to compare TLRY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TLRY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (24.3%).


Return on Equity

High ROE: TLRY has a negative Return on Equity (-31.95%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: TLRY is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: TLRY is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Tilray's financial position?


Financial Position Analysis

Short Term Liabilities: TLRY's short term assets ($358.6M) exceeds its short term liabilities ($175.9M)

Long Term Liabilities: TLRY's short term assets (358.6M) do not cover its long term liabilities (488.1M)


Debt to Equity History and Analysis

Debt Level: TLRY's debt to equity ratio (118.1%) is considered high

Reducing Debt: Insufficient data to determine if TLRY's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: TLRY has a high level of physical assets or inventory.

Debt Coverage by Assets: TLRY's debt is not covered by short term assets (assets are 0.8x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TLRY has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: TLRY has sufficient cash runway for 2.737462 years if free cash flow continues to reduce at historical rates of -103.1% each year.


Next Steps

Dividend

What is Tilray's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate TLRY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate TLRY's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if TLRY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TLRY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TLRY's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Tilray's salary, the management and board of directors tenure and is there insider trading?

0.8yrs

Average management tenure


CEO

Brendan Kennedy (47yo)

1.8yrs

Tenure

US$31,817,459

Compensation

Mr. Brendan Kennedy serves as President and Chief Executive Officer and Director of Tilray, Inc. since January 2018 and serves as its Chairman of the Board. He serves as the Chief Executive Officer and Dir ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Brendan's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Brendan's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

0.8yrs

Average Tenure

49yo

Average Age

Experienced Management: TLRY's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Age and Tenure

1.4yrs

Average Tenure

47yo

Average Age

Experienced Board: TLRY's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Mark Castaneda (54yo)

    CFO & Treasurer

    • Tenure: 1.6yrs
    • Compensation: US$4.54m
  • Ed Pastorius (51yo)

    Chief Revenue Officer

    • Tenure: 1.6yrs
    • Compensation: US$2.77m
  • Brendan Kennedy (47yo)

    Chairman

    • Tenure: 1.8yrs
    • Compensation: US$31.82m
  • Greg Christopher

    Executive Vice President of Operations

    • Tenure: 0.8yrs
  • Rita Seguin

    Executive Vice President of Human Resources

    • Tenure: 0.8yrs
  • Dara Redler

    General Counsel & Corporate Secretary

    • Tenure: 0.8yrs
  • Sascha Mielcarek

    Managing Director of Europe

    • Tenure: 0.7yrs
  • Andrew Pucher (36yo)

    Chief Corporate Development Officer

    • Tenure: 0.6yrs
  • Josh Eades

    Chief Science Officer

    • Tenure: 0yrs
  • John Andonoff

    Senior Vice President of Global Medical Sales Development

    • Tenure: 0yrs

Board Members

  • Praveen Anand

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Brendan Kennedy (47yo)

    Chairman

    • Tenure: 1.8yrs
    • Compensation: US$31.82m
  • Catherine Lord

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Abraham Chachoua

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Michael Auerbach (43yo)

    Director

    • Tenure: 1.7yrs
    • Compensation: US$522.26k
  • Rebekah Dopp (42yo)

    Director

    • Tenure: 1.4yrs
    • Compensation: US$295.35k
  • Scotty Greenwood (53yo)

    Director

    • Tenure: 1.4yrs
    • Compensation: US$297.35k
  • Christine St.Clare (69yo)

    Director

    • Tenure: 1.3yrs
    • Compensation: US$298.60k
  • Orrin Devinsky

    Chairman of Medical Advisory Board

    • Tenure: 0yrs
  • Elizabeth Hale

    Member of Medical Advisory Board

    • Tenure: 0yrs

Company Information

Tilray, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Tilray, Inc.
  • Ticker: TLRY
  • Exchange: NasdaqGS
  • Founded: 2018
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.106b
  • Shares outstanding: 98.56m
  • Website: https://www.tilray.com

Number of Employees


Location

  • Tilray, Inc.
  • 1100 Maughan Road
  • Nanaimo
  • British Columbia
  • V9X IJ2
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TLRYNasdaqGS (Nasdaq Global Select)YesClass 2 Common StockUSUSDJul 2018
2HQDB (Deutsche Boerse AG)YesClass 2 Common StockDEEURJul 2018
2HQSWX (SIX Swiss Exchange)YesClass 2 Common StockCHCHFJul 2018
0Z6YLSE (London Stock Exchange)YesClass 2 Common StockGBUSDJul 2018
2HQXTRA (XETRA Trading Platform)YesClass 2 Common StockDEEURJul 2018

Biography

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products to patients, physicians, pharmacies, governments, and hospitals; and for ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 00:38
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.